echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lansheng biomedical has completed tens of millions of a rounds of financing and is committed to the research and development of innovative drugs for neuropsychiatric diseases

    Lansheng biomedical has completed tens of millions of a rounds of financing and is committed to the research and development of innovative drugs for neuropsychiatric diseases

    • Last Update: 2019-01-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to vcpeat, Lansheng biomedical, which is committed to developing central nervous system drugs, recently announced the completion of tens of millions of yuan a round of financing, which is led by Yipu capital and co invested by qianrong capital and existing northeast Aurora venture capital This round of financing will accelerate the clinical R & D Progress of Lansheng in the innovative varieties of dm-8021 and ls-196, as well as the localization of multi-component / multi-phase slow controlled release and long-term injection preparation technology platforms and varieties, and launch the corresponding listed varieties, while completing the construction of the company's Suzhou park base With this round of financing in place, Mr Lin Xianghong, founding partner of Yipu capital, will join the board of directors of Lansheng "We are very pleased to join hands with Yipu capital and qianrong capital, which are important investors in the pharmaceutical industry, to provide better innovative drugs for patients with severe central nervous system diseases At the same time, we also thank the existing shares of northeast Aurora venture capital for their continued support!" Dr Xu Jiangping, founder and CEO of Lansheng, said: "this round of successful financing reflects the significant progress that Lansheng pharmaceutical has made in promoting the company's new drug pipeline in the past two years The company's innovative dm-8021 preclinical research data prove that the new compound with this structure is safe and effective, with clear target, outstanding advantages, good drug preparation and great potential Its efficacy and safety are superior to the anticholinergic drugs currently used in the clinical first line In addition, ls-196, a key project of the company, is a brand-new target mechanism compound with completely independent intellectual property rights of the company All pre clinical research work has been completed, and now an ind application has been submitted " Ls-196, as a highly selective enzyme allosteric modulator, has clear efficacy and rapid onset, which is expected to break through the dilemma of delayed onset and drug resistance of existing antidepressants in clinical practice and occupy the drug market that does not meet the needs of patients At the same time, several high-end preparations of the company are in the clinical pre be stage This will greatly enrich the company's product line construction and lay the foundation for the company's development This financing will promote the clinical development of products at full speed and bring good news to patients as soon as possible Mr Lin Xianghong, capital of Yipu, said: "the market potential of nervous system drugs is huge, and there are many areas where the demand for treatment and patients has not been met Lan Sheng team, led by Dr Xu Jiangping, has worked in the field of nervous system drug research and development for many years, accumulated rich experience and formed a rich product pipeline We very much recognize and admire the persistence and efforts of Lansheng team in the field of innovative drug research and development, and we are glad to help Lansheng in drug research and development, clinical promotion and production construction May Lansheng make further efforts to bring new and better medicines to patients as soon as possible " Ms Ye Xiaoming, qianrong capital: "it's a great honor for qianrong capital to join the Lansheng family and bring good news to patients with central nervous system diseases around the world Lansheng pharmaceutical has a number of new drug R & D pipelines including depression, Alzheimer's disease, Parkinson's disease, stroke, etc Dr Xu Jiangping and his core team are not only in the leading position in the research field of central nervous diseases, but also have rich experience and outstanding achievements in new drug R & D in this field Qianrong capital is very optimistic about the future development of Lansheng pharmaceutical Exhibition " As two consecutive rounds of investors, northern lights venture capital has a high degree of affirmation for the Lansheng team "Central nervous system diseases are the main diseases that affect human health in the future, and drug development in this area will also become an important direction in the field of medicine," said Mr Deng Feng, founder Lansheng team has been working in this field for more than 20 years, with very rich experience in drug development The company has a rich product line, and some of its products are in the leading position in the world It is believed that Lansheng medicine can bring new treatment programs and benefits to patients with central nervous system diseases all over the world " About Lansheng biomedical, founded in 2012, Lansheng biomedical is positioned as a leader in the research and development of innovative drugs for neuropsychiatric diseases The company has a highly educated, high-tech and experienced R & D team, whose business expertise covers small molecule design and synthesis, preliminary screening, pharmacokinetics evaluation, pharmacology and toxicology evaluation, registration and application to clinical trial supervision, etc Since its inception, it has insisted on the development of innovative drugs with independent intellectual property rights, and has established a number of small molecule compounds Library of more than 800 kinds The company is committed to developing small molecular compounds with new structure, strong market competitiveness and indications of chronic diseases of the nervous and mental system, promoting the listing of new drugs with independent intellectual property rights, and promoting the strategic transformation of the pharmaceutical industry to independent innovation About Yipu capital, founded in 2016, Yipu capital is an investment management company focusing on private equity investment and venture capital Yipu capital has a wide and in-depth layout in the fields of biomedicine and medical devices It has invested in a number of early projects with innovative technologies, independent intellectual property rights and top teams in the fields of tumor, cardiovascular, diabetes, central nervous system, autoimmune system, etc., and has also carried out layout in the fields of medical services and drug circulation Yipu capital is committed to providing the invested enterprises with effective industry resources, strategic planning, market development and other value-added services to help them grow into innovative enterprises with first-class international competitiveness About qianrong capital qianrong capital was founded in 2010 It is the executive director unit of China Private Investment Association, vice chairman unit of Suzhou Venture Capital Association and director unit of Suzhou Equity Investment Association At present, it manages 7 venture capital funds and equity investment funds, with a management scale of more than 2 billion yuan Among the projects invested, 9 companies, including newway, Everbright, xuchuang technology, and madiston, have entered the Shanghai Shenzhen Stock Exchange or the Hong Kong stock exchange In addition to forming its own unique standard system in project judgment, qianrong capital attaches great importance to post investment management Ye Xiaoming, chairman of qianrong capital, describes qianrong's investment philosophy as "two investment and eight branches" In the development process of real enterprises, there are many rapids and dangerous shoals Qianrong capital has always spared no effort to give enterprises support in standardized management, capital market docking, market resources, human resources and other aspects It is in the same boat with entrepreneurs and is unanimously rated as the "best investor" by the invested enterprises About Northern Lights venture capital, founded by Mr Deng Feng in 2005, is a venture capital organization with the purpose of "achieving world-class entrepreneurs and cultivating world-class Chinese enterprises" At present, it manages 5 US dollar funds and 5 RMB funds, with assets under management of more than 30 billion yuan It has long been focused on investing in early stage, scientific and technological innovation oriented excellent enterprises, emphasizing "team, market, innovation" and growing together with enterprises Up to now, Aurora Borealis has invested more than 250 excellent enterprises in TMT, advanced technology, medical and health fields, including meituan.com, zhongkechuangda, chinaonline, BGI, blue harbor interactive, Spreadtrum communication, Apus, ocean music, Hanting Hotel, Zhaoyi innovation, dianrong.com, CITIC medicine, vipkid, etc.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.